Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong Mei Yi

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|October 24, 2022
Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphomaMeng-Ke Liu, Li-Li Cheng, Hong-Mei Yi, et al.
Blood|May 21, 2026
N6-methyladenosine reader IGF2BP2 in T-cell lymphomaSong Hu, Yao Qin, Hong-Mei Yi, et al.
Oncotarget|August 29, 2015
MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathwayJia-Quan Qu, Hong-Mei Yi, Xu Ye, et al.
Blood Advances|January 3, 2024
Biological signatures of the International Prognostic Index in diffuse large B-cell lymphomaYue Wang, Qing Shi, Zi-Yang Shi, et al.
Molecular Cancer Therapeutics|August 26, 2015
MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT SignalingJia-Quan Qu, Hong-Mei Yi, Xu Ye, et al.
International Journal of Biological Sciences|August 8, 2024
<i>KMT2D</i> mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axisQing-Xiao Liu, Yue Zhu, Hong-Mei Yi, et al.
Blood|February 27, 2026
CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell LymphomaXiang Li, Mengke Liu, Qing Shi, et al.
Signal Transduction and Targeted Therapy|March 6, 2024
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphomaJie Xiong, Shu Cheng, Xiao Gao, et al.
Genome Medicine|October 24, 2025
Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvementRui-Chi Li, Wei Tang, Hui-Lai Zhang, et al.
Cancer Cell|September 29, 2023
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trialMu-Chen Zhang, Shuang Tian, Di Fu, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|October 24, 2022
Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphomaMeng-Ke Liu, Li-Li Cheng, Hong-Mei Yi, et al.
Blood|May 21, 2026
N6-methyladenosine reader IGF2BP2 in T-cell lymphomaSong Hu, Yao Qin, Hong-Mei Yi, et al.
Oncotarget|August 29, 2015
MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathwayJia-Quan Qu, Hong-Mei Yi, Xu Ye, et al.
Blood Advances|January 3, 2024
Biological signatures of the International Prognostic Index in diffuse large B-cell lymphomaYue Wang, Qing Shi, Zi-Yang Shi, et al.
Molecular Cancer Therapeutics|August 26, 2015
MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT SignalingJia-Quan Qu, Hong-Mei Yi, Xu Ye, et al.
International Journal of Biological Sciences|August 8, 2024
<i>KMT2D</i> mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axisQing-Xiao Liu, Yue Zhu, Hong-Mei Yi, et al.
Blood|February 27, 2026
CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell LymphomaXiang Li, Mengke Liu, Qing Shi, et al.
Signal Transduction and Targeted Therapy|March 6, 2024
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphomaJie Xiong, Shu Cheng, Xiao Gao, et al.
Genome Medicine|October 24, 2025
Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvementRui-Chi Li, Wei Tang, Hui-Lai Zhang, et al.
Cancer Cell|September 29, 2023
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trialMu-Chen Zhang, Shuang Tian, Di Fu, et al.
Pageof 4